A report released by the IMS Institute of Healthcare Informatics found that U.S. spending on drugs dropped for the first time since the group began reporting on prices in 1957. The decline was attributed to the expiry of patents of big-name treatments and the availability of generics. Spending totaled $325.8 billion in 2012, a 1% drop from the previous year.

Related Summaries